• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Financial Report: PPD

contractpharmaOctober 30, 2020

Tag: PPD , Financial Report , revenues

PPD

3Q Revenues: $1.2 billion (+21%)

3Q Earnings: $9.1 million (-45%)

YTD Revenues: $3.3 billion (+11%)

YTD Earnings: $58.1 million (+69%)

Comments: Clinical Development Services revenue was $1.0 billion in the quarter, up 19% and Laboratory Services revenue was $225.2 million, up 27%. Net authorizations of $1.2 billion, representing 33% growth over third quarter 2019 and resulting in a net book-to-bill ratio of 1.35x on a historical basis. Ending backlog of $7.9 billion, representing 16% growth over third quarter 2019.

Previous:TherapeutAix Expands R&D Network

Next:Avomeen Names SVP of Lab Operations

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Financial Report: PPD | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

TB-PPD(Purified Protein Derivative of Tuberlin)

TB-PPD(Purified Protein Derivative of Tuberlin)
P-phenylenediamine(PPD) (106-50-3)

P-phenylenediamine(PPD) (106-50-3)
P-phenylenediamine(PPD)Lump (106-50-3)

P-phenylenediamine(PPD)Lump (106-50-3)
P-PHENYLENE DIAMINE(PPDA) 99.5PCT

P-PHENYLENE DIAMINE(PPDA) 99.5PCT
P-PHENYLENE DIAMINE SULFATE (PPDS)

P-PHENYLENE DIAMINE SULFATE (PPDS)
Protopanaxadiol(APPD)-40%

Protopanaxadiol(APPD)-40%
P-PHENYL DIISOCYANATE（PPDI）99PCT

P-PHENYL DIISOCYANATE（PPDI）99PCT
2-NITRO-P-PHENYLENE DIAMINE SULFATE (2NPPDS)

2-NITRO-P-PHENYLENE DIAMINE SULFATE (2NPPDS)
AMPPD

AMPPD
2-Chloro-p-phenylenediamine sulfate（OCPPDS) (61702-44-1)

2-Chloro-p-phenylenediamine sulfate（OCPPDS) (61702-44-1)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service